The αv integrin antagonists as novel anticancer agents: an update

Author： Kerr Janet S   Slee Andrew M   Mousa Shaker A  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.11, Iss.12, 2002-12, pp. : 1765-1774

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Small molecule v integrin antagonists: novel anticancer agents

By Kerr J.S.   Slee A.M.   Mousa S.A.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 6, 2000-06 ,pp. : 1271-1279

Informa Healthcare

Access to resources Recommend Favorite

Bradykinin Antagonists as Anti-Cancer Agents

By  

Current Pharmaceutical Design, Vol. 9, Iss. 25, 2003-10 ,pp. : 2036-2042

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Integrin Antagonists Derived from Thrombospondins

By  

Current Pharmaceutical Design, Vol. 11, Iss. 7, 2005-03 ,pp. : 849-866

Bentham Science Publishers

Access to resources Recommend Favorite

Progesterone Receptor Agonists and Antagonists as Anticancer Agents

By  

Mini Reviews in Medicinal Chemistry, Vol. 10, Iss. 6, 2010-06 ,pp. : 506-517

Bentham Science Publishers

Access to resources Recommend Favorite

Topoisomerase inhibitors as anticancer agents: a patent update

By Khadka Daulat B   Cho Won-Jea  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 8, 2013-08 ,pp. : 1033-1056

Informa Healthcare

Access to resources Recommend Favorite